We are engaged in the R & D, industrialization and sales of chemical generic drugs. We have a first-class chemical generic technology team and a professional drug sales company with GSP qualification. We adopt the unique "self-supporting R & D, sales + outsourcing production" mode ("HISCO mode"), light asset operation, fully control the high profit links of the industrial chain and constantly list new varieties, So that the company has sustained rapid growth momentum.

In recent years, the team has developed and reserved a number of products, forming a complete R & D pipeline, covering cardiovascular disease, gynecology, cancer, analgesia, gastrointestinal, degenerative diseases and other fields.

In 2016, ibandronate sodium injection (shangruiyou) and ketorolac tromethamine injection (shangruixin) were officially sold